Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017

  Рет қаралды 23,525

U.S. Food and Drug Administration

U.S. Food and Drug Administration

Күн бұрын

Maria Cecilia Tami and Balajee Shanmugam review the Chemistry, Manufacturing and Controls (CMC) portion of a drug intended for use under an investigational new drug application (IND). The review resides in the Office of New Drug Products (ONDP) and in the Office of Biotechnological Products (OBP). ONDP reviews small molecules while biologics are reviewed by OBP.
This session discusses the CMC information for small molecules and biologics required for an IND per 21 CFR 312.23, especially with reference to the drug substance (characterization, manufacturing, testing, and stability) and drug product (composition, manufacture, testing and stability), to support that the investigational drug is reasonably safe for use in a clinical trial. The presentation will also discuss case studies of CMC related clinical hold issues.
-------------------------
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming training and free continuing education credits: www.fda.gov/cd...
CDER SBIA 2017 Playlist: • 2017 CDER Small Busine...
LinkedIn: / cder-small-business-an...
Training resources: www.fda.gov/cd...
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.go...
Email: CDERSBIA@fda.hhs.gov
Phone: (301) 796-6707 I (866) 405-5367

Пікірлер
Overview of Non-clinical Assessment in Drug Development (8/14) REdI 2017
54:28
U.S. Food and Drug Administration
Рет қаралды 16 М.
Chemistry, Manufacturing, and Controls (CMC) for an IND (7of14) REdI 2018
1:19:35
U.S. Food and Drug Administration
Рет қаралды 28 М.
UFC 287 : Перейра VS Адесанья 2
6:02
Setanta Sports UFC
Рет қаралды 486 М.
Jaidarman TOP / Жоғары лига-2023 / Жекпе-жек 1-ТУР / 1-топ
1:30:54
번쩍번쩍 거리는 입
0:32
승비니 Seungbini
Рет қаралды 182 МЛН
Overview of the Guidance for Industry: Control of Nitrosamine Impurities in Human Drugs
1:22:14
U.S. Food and Drug Administration
Рет қаралды 16 М.
CMC - NDA requirements and Common Pitfalls of BLAs (14of15) REdI - May 29-30, 2019
1:10:48
U.S. Food and Drug Administration
Рет қаралды 10 М.
Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018
44:31
Common CMC (Quality) Issues and How to Avoid Them Part I (12of16) Generic Drugs Forum
57:58
U.S. Food and Drug Administration
Рет қаралды 7 М.
CMC Considerations for Biotechnology Product Development: A Regulatory Perspective
56:31
U.S. Food and Drug Administration
Рет қаралды 3,6 М.
Regulatory Considerations for Impurity Qualification: ICH Q3A/Q3C/Q3D, RLD & MDD
28:12
U.S. Food and Drug Administration
Рет қаралды 10 М.
Designing First-In-Human Trials for Small Molecules and Biologics
37:34
U.S. Food and Drug Administration
Рет қаралды 11 М.
Post-approval Considerations for Changes to Manufacturing Process and Facilities - REdI 2020
28:11
Electronic Common Technical Document (eCTD) and Study Data (7of15) RedI - May 29-30, 2019
55:56
U.S. Food and Drug Administration
Рет қаралды 12 М.
Formal Meetings for PDUFA Products and Communication Best Practices (4of14) REdI 2018
39:14
U.S. Food and Drug Administration
Рет қаралды 3 М.
UFC 287 : Перейра VS Адесанья 2
6:02
Setanta Sports UFC
Рет қаралды 486 М.